Some unused narcotics should go down the drain, FDA says

Traynor, Kate
December 2009
American Journal of Health-System Pharmacy;12/1/2009, Vol. 66 Issue 23, p2070
Academic Journal
The article reports on the request of the Food and Drug Administration to dispose certain drugs due to health risk in the U.S. It points out that leftover narcotics should be remove such as flushing or pouring them down a sink since some of these drugs contain high-potency opioids which cause harm of death if a single dose is taken. Toxicologist Tim Kropp suspects that over 100 children die each year for ingesting leftover medicine but stresses there is no real statistics for the problem.


Related Articles

  • Accutane Drug Guide Flags Psych Risks.  // RN;Aug2002, Vol. 65 Issue 8, p95 

    Reports the issuance of Food and Drug Administration of risk management guide to help clinician recognize psychiatric disorders in patients using isotretinoin in the U.S. Cause of the acne drug; Advice on the ways to spot signs of depression; Inclusion of recommendations for referring patients...

  • News in brief . . .  // Reactions Weekly;5/22/2004, Issue 1002, p2 

    Presents news briefs on the pharmaceutical industry as of May 2004. Warning issued to several hospitals in Canada on the adverse effects of muromonab CD3 to pediatric patients; Argument raised by the Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration...

  • ProSanos Launches Pharmacovigilance Tool. Neuer, Ann // Bio-IT World;Sep2007, Vol. 6 Issue 7, p32 

    The article focuses on Claerity, a pharmacovigilance product offered by ProSanos, a provider of safety and risk management services. The product, which was launched by the company in June 2007, runs on top of the U.S. Food and Drug Association's (FDA) Adverse Event Reporting System (AERS)...

  • FDA Announces Vytorin Investigation.  // Infectious Disease Alert;Oct2008 Primary Care, Vol. 13 Issue 10, p1 

    The article reports on the plan of the U.S. Food and Drug Administration (FDA) to investigate a report from the Simbastatin and Ezetimibe in Aortic Stenosis (SEAS) trial of the possible link between the use of Vytorin and increased incidence of cancer. The SEAS trial was conducted to see if...

  • FDA Announces Vytorin Investigation.  // Neurology Alert;Oct2008 Pharmacology Watch, p1 

    This article reports on the plan of the U.S. Food and Drug Administration (FDA) to investigate a report from the SEAS trial (Simvastatin and Ezetimibe in Aortic Stenosis) of the possible association between the use of Vytorin and increased incidence of cancer. The SEAS trial was designed to see...

  • FDA links arthritis drugs to infections, deaths. Pfeiffer, Naomi // Dermatology Times;Jan2001, Vol. 22 Issue 1, p16 

    Focuses on the influence of arthritis drug agents on infectious complications resulting to death in Philadelphia, Pennsylvania. Effect of tumor-necrosis factor on rheumatoid arthritis patients; Accounts on opportunistic infections following drug treatment; Discussion on the package labelling...

  • Alert over PPIs with clopidogrel. Praities, Nigel // Pulse;2/4/2009, Vol. 69 Issue 3, p7 

    The article reports on the recommendation of the U.S. Food and Drug Administration (FDA) that general practitioners (GPs) should review all patients taking proton pump inhibitors with clopidogrel. Results of a study concerning the effect of the drug show that the use of PPI had adverse...

  • REMS, Patient Safety, and Professional Liability Risks. Heagerty, Kathryn E. // Innovations in Clinical Neuroscience;Mar2012, Vol. 9 Issue 3, p27 

    The article provides an answer to a question of what Risk Evaluation and Mitigation Strategy (REMS) is and the reasons as to why it is so important.

  • Adverse Drug Event Monitoring at the Food and Drug Administration. Ahmad, Syed Rizwanuddin // JGIM: Journal of General Internal Medicine;Jan2003, Vol. 18 Issue 1, p57 

    The Food and Drug Administration (FDA) is responsible not only for approving drugs but also for monitoring their safety after they reach the market. The complete adverse event profile of a drug is not known at the time of approval because of the small sample size, short duration, and limited...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics